Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and ...

AstraZeneca Plc's AZN Bydureon BCise (exenatide 2 mg prolonged-release suspension for injection) is indicated for type-2 diabetes. Novo Nordisk A/S' NVO semaglutide is approved as Ozempic and ...

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

Bydureon (exenatide), a weekly type 2 diabetes GLP-1 class injection, is nearing the end of its patent life and is also under threat from Novo Nordisk’s next-generation weekly jab, semaglutide.

It was made into a drug called exenatide and in 2005 ... which was a daily injection, and long-acting GLP-1 agonists such as semaglutide, a weekly injection. As well as increasing insulin from ...

Common side-effects were nausea and vomiting. However, exenatide has to be injected twice daily owing to its short half-life. An injectable long-acting release version, exenatide LAR, with a more ...

The first RCT, focusing on exenatide, reported no significant reduction ... Their availability in oral and injectable formulations also enhances patient adherence. However, cost and insurance ...

In fact, the first one to hit the market was a drug called Exenatide. It was approved in ... Moving into Phase 3 should be very soon with the injectable version. They could be out in the not ...

The device, dubbed NPM-115, is a miniature sub-dermal implant that delivers exenatide, a glucagon-like peptide-1 receptor agonist (GLP-1RA). Image credit: Shutterstock / Formatoriginal. A day after ...

The oral administration of exenatide was compared with the subcutaneous injection (s.c.) of 10 µg/kg exenatide in solution or as Byetta. It is of the utmost importance to note that our innovative ...